RecruitingPhase 4NCT07034677

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

Sponsor

Lars Rejnmark

Enrollment

24 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Hypoparathyroidism Post-surgical

Summary

The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.

Eligibility

Min Age: 18 Years

Inclusion Criteria8

Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago
Age ≥ 18 years
Require treatment with active vitamin D ≥ 1 µg/day
Ionized plasma calcium between 1.15-1.25 mmol/L
(OH)D vitamin ≥ 50 nmol/L
Plasma magnesium \> 0.65 mmol/L
Able to read and understand Danish
Willing and able to sign the informed consent form

Exclusion Criteria14

Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3
Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago
Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago
Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg
Plasma potassium \< 3.5 mmol/L
Any current disease that might affect the calcium metabolism such as but not limited to:
Recent prolonged immobility
Untreated diabetes (HbA1c \> 53 mmol/mol)
Severe liver disease or hepatic encephalopathy
Untreated thyroid disease
Current disease that might affect gastrointestinal absorption
Use of medications such as lithium or diuretics within 4 weeks prior to start of treatment
Known allergy or sensitivity to Indapamide, its excipients or sulfonamides
Known galactosemia, lactase deficiency, or glucose-galactose malabsorption